MX2020010563A - Derivados de pirazolo-triazina y/o pirazolo-pirimidina farmaceuticamente activos. - Google Patents
Derivados de pirazolo-triazina y/o pirazolo-pirimidina farmaceuticamente activos.Info
- Publication number
- MX2020010563A MX2020010563A MX2020010563A MX2020010563A MX2020010563A MX 2020010563 A MX2020010563 A MX 2020010563A MX 2020010563 A MX2020010563 A MX 2020010563A MX 2020010563 A MX2020010563 A MX 2020010563A MX 2020010563 A MX2020010563 A MX 2020010563A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrazolo
- pyrimidine derivatives
- triazine
- pharmaceutically active
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656041P | 2018-04-11 | 2018-04-11 | |
| PCT/EP2019/059289 WO2019197546A1 (en) | 2018-04-11 | 2019-04-11 | Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010563A true MX2020010563A (es) | 2020-10-22 |
Family
ID=66334384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010563A MX2020010563A (es) | 2018-04-11 | 2019-04-11 | Derivados de pirazolo-triazina y/o pirazolo-pirimidina farmaceuticamente activos. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11858937B2 (enExample) |
| EP (1) | EP3774809A1 (enExample) |
| JP (2) | JP7406501B2 (enExample) |
| KR (1) | KR102966358B1 (enExample) |
| CN (1) | CN112334471A (enExample) |
| AU (1) | AU2019250504B2 (enExample) |
| BR (1) | BR112020020645A2 (enExample) |
| CA (1) | CA3095426A1 (enExample) |
| IL (2) | IL299105B2 (enExample) |
| MX (1) | MX2020010563A (enExample) |
| MY (1) | MY207194A (enExample) |
| PH (1) | PH12020551638A1 (enExample) |
| SG (1) | SG11202009466UA (enExample) |
| WO (1) | WO2019197546A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202146416A (zh) * | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | 吡唑并三𠯤 |
| GB201918541D0 (en) | 2019-12-16 | 2020-01-29 | Carrick Therapeutics Ltd | Therapeutic compounds and their use |
| EP4255909A1 (en) * | 2020-12-02 | 2023-10-11 | Qurient Co. Ltd. | Compounds having cyclin-dependent kinase(cdk)-inhibitory function |
| WO2022248682A1 (en) * | 2021-05-28 | 2022-12-01 | Qurient Co., Ltd. | Compounds for degradation of cyclin-dependent kinase 7 (cdk7) |
| US20250042903A1 (en) * | 2021-06-17 | 2025-02-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Triazine inhibitors of cyclin-dependent kinases |
| WO2023175173A1 (en) * | 2022-03-18 | 2023-09-21 | Qurient Co., Ltd. | Cdk7 inhibitors for antiviral treatment |
| US20260041693A1 (en) | 2022-08-05 | 2026-02-12 | Qurient Co., Ltd. | Combination therapy of cdk7 inhibitors with other anti-cancer therapies |
| KR20240095030A (ko) | 2022-12-15 | 2024-06-25 | 부산대학교 산학협력단 | 간과 신장의 염증 및 섬유화 치료 효과가 있는 신규 트리아진 유도체 및 이의 제조방법 |
| CN120752238A (zh) * | 2023-02-20 | 2025-10-03 | 江苏正大丰海制药有限公司 | 作为cdk7激酶抑制剂的杂芳环化合物及其制备和应用 |
| CN120712267A (zh) * | 2023-02-21 | 2025-09-26 | 杭州德睿智药科技有限公司 | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 |
| WO2025040170A1 (zh) * | 2023-08-24 | 2025-02-27 | 杭州德睿智药科技有限公司 | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 |
| WO2025162425A1 (zh) * | 2024-02-01 | 2025-08-07 | 广州费米子科技有限责任公司 | 吡唑并嘧啶化合物作为tyk2抑制剂 |
| CN119606955A (zh) * | 2024-11-13 | 2025-03-14 | 南方医科大学 | Txd-174在制备治疗和/或预防黄病毒属病毒感染产品中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US615968A (en) | 1898-12-13 | Apparatus for treating ores | ||
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| US8673924B2 (en) | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| JP2010529140A (ja) * | 2007-06-05 | 2010-08-26 | エモリー・ユニバーシテイ | サイクリン依存性キナーゼの選択的阻害剤 |
| EP2634189A1 (en) | 2012-03-01 | 2013-09-04 | Lead Discovery Center GmbH | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors |
| EP2634190A1 (en) | 2012-03-01 | 2013-09-04 | Lead Discovery Center GmbH | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors |
| GB201403093D0 (en) * | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EP3805218A1 (en) | 2014-04-05 | 2021-04-14 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| EP3268000B1 (en) * | 2015-03-09 | 2021-08-04 | Aurigene Discovery Technologies Limited | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors |
| WO2019035866A1 (en) | 2017-08-15 | 2019-02-21 | The Brigham & Women's Hospital, Inc. | COMPOSITIONS AND METHODS FOR TREATING THE TUBEROUS SCLEROSIS COMPLEX |
-
2019
- 2019-04-11 MY MYPI2020005131A patent/MY207194A/en unknown
- 2019-04-11 CN CN201980039675.8A patent/CN112334471A/zh active Pending
- 2019-04-11 KR KR1020207032377A patent/KR102966358B1/ko active Active
- 2019-04-11 US US17/045,009 patent/US11858937B2/en active Active
- 2019-04-11 IL IL299105A patent/IL299105B2/en unknown
- 2019-04-11 SG SG11202009466UA patent/SG11202009466UA/en unknown
- 2019-04-11 MX MX2020010563A patent/MX2020010563A/es unknown
- 2019-04-11 EP EP19720424.1A patent/EP3774809A1/en active Pending
- 2019-04-11 BR BR112020020645-8A patent/BR112020020645A2/pt unknown
- 2019-04-11 AU AU2019250504A patent/AU2019250504B2/en active Active
- 2019-04-11 JP JP2020555188A patent/JP7406501B2/ja active Active
- 2019-04-11 WO PCT/EP2019/059289 patent/WO2019197546A1/en not_active Ceased
- 2019-04-11 CA CA3095426A patent/CA3095426A1/en active Pending
-
2020
- 2020-09-30 IL IL277694A patent/IL277694A/en unknown
- 2020-10-05 PH PH12020551638A patent/PH12020551638A1/en unknown
-
2023
- 2023-08-14 JP JP2023131905A patent/JP2023138859A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020020645A2 (pt) | 2021-01-12 |
| SG11202009466UA (en) | 2020-10-29 |
| CN112334471A (zh) | 2021-02-05 |
| CA3095426A1 (en) | 2019-10-17 |
| AU2019250504B2 (en) | 2023-05-18 |
| JP2023138859A (ja) | 2023-10-02 |
| IL299105B2 (en) | 2024-02-01 |
| KR102966358B1 (ko) | 2026-05-15 |
| JP2021521129A (ja) | 2021-08-26 |
| WO2019197546A1 (en) | 2019-10-17 |
| KR20200143429A (ko) | 2020-12-23 |
| US20210139483A1 (en) | 2021-05-13 |
| IL299105B1 (en) | 2023-10-01 |
| US11858937B2 (en) | 2024-01-02 |
| PH12020551638A1 (en) | 2021-07-26 |
| IL277694A (en) | 2020-11-30 |
| JP7406501B2 (ja) | 2023-12-27 |
| EP3774809A1 (en) | 2021-02-17 |
| MY207194A (en) | 2025-02-05 |
| AU2019250504A1 (en) | 2020-10-15 |
| NZ768400A (en) | 2024-07-05 |
| IL299105A (en) | 2023-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020010675A (es) | Derivados de pirazolo-triazina y/o pirazolo-pirimidina como inhibidor selectivo de cinasa dependiente de ciclina. | |
| MY207194A (en) | Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives | |
| CO2021016594A2 (es) | Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina | |
| MX347359B (es) | Derivados de pirazolo-triazina como inhibidores selectivos de cinasas dependientes de ciclina. | |
| CO2022001094A2 (es) | Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas | |
| UY33286A (es) | Derivados de triazina disustituidos farmaceuticamente activos | |
| CL2019002150A1 (es) | Derivados de 3-fenil-4-amino-imidazo[4,5-c]piridin-2-ona y 7-fenil-6-amino-purin-8-ona sustituidos, inhibidores de tirosinacinasas, en particular tirosinacinasa de bruton (btk); composiciones que contiene los compuestos; y uso para enfermedades tales como cáncer, autoinmunitarias, inflamatorias y tromboembólicas. (divisional solicitud 201703073) | |
| MX2019005154A (es) | Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2. | |
| NI202000078A (es) | Compuestos heteroaril tetracíclicos | |
| MX381849B (es) | Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso. | |
| GEAP202215630A (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| UY33414A (es) | ?profármacos de nucleósidos 1'?carba sustituidos para tratamiento antiviral, composiciones y su uso?. | |
| MX2021004487A (es) | Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion. | |
| AR101261A1 (es) | Compuesto de tetrahidropirrolo[1,2:3,4]imidazo[1,2-c]pirimidin-1(6h)-ona y composición farmacéutica que lo comprende | |
| ECSP22009803A (es) | [1,2,4]triazolo[1,5-c]quinazolin-5-aminas | |
| MX2023005626A (es) | Derivados de pirazolo[1.5-a]pirazina como inhibidores de la btk. | |
| CL2016000495A1 (es) | Compuestos derivados de triazolo[4,5-d]pirimidina, agonistas de receptor cb2; proceso de preparación; composición que los comprende y el uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamación, diabetes mellitus, entre otras enfermedades. | |
| MX2019005123A (es) | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2. | |
| CL2017001543A1 (es) | Formulaciones farmacéuticas de inhibidores de la cinasa relacionada con tropomiosina (trk) | |
| AR117844A1 (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina | |
| MX2020007443A (es) | Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de vasculitis y enfermedades inflamatorias. | |
| MX2019005115A (es) | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2. | |
| EA201792087A1 (ru) | ПРОИЗВОДНЫЕ 7-(МОРФОЛИН-4-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИМИДИНА, ПРИГОДНЫЕ ДЛЯ ЛЕЧЕНИЯ ИММУННЫХ ИЛИ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ИЛИ РАКА | |
| DOP2021000162A (es) | Proceso para preparar rogaratinib y sus estados sólidos | |
| AR107199A1 (es) | Una forma cristalina de diclosulam, un proceso para su preparación y uso de este |